Your browser is no longer supported. Please, upgrade your browser.
Settings
PHAT Phathom Pharmaceuticals, Inc. daily Stock Chart
PHAT [NASD]
Phathom Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-8.27 Insider Own20.10% Shs Outstand25.61M Perf Week9.49%
Market Cap1.06B Forward P/E- EPS next Y-3.09 Insider Trans3.26% Shs Float23.55M Perf Month-5.41%
Income-207.40M PEG- EPS next Q-0.67 Inst Own76.70% Short Float3.70% Perf Quarter-18.53%
Sales- P/S- EPS this Y88.20% Inst Trans-0.37% Short Ratio12.68 Perf Half Y45.92%
Book/sh7.36 P/B5.15 EPS next Y-16.60% ROA-97.20% Target Price38.33 Perf Year-
Cash/sh8.82 P/C4.30 EPS next 5Y- ROE-175.50% 52W Range18.51 - 64.54 Perf YTD21.84%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-41.21% Beta-
Dividend %- Quick Ratio18.80 Sales past 5Y- Gross Margin- 52W Low104.97% ATR2.11
Employees25 Current Ratio18.80 Sales Q/Q- Oper. Margin- RSI (14)60.38 Volatility5.41% 5.95%
OptionableYes Debt/Eq0.25 EPS Q/Q75.70% Profit Margin- Rel Volume1.77 Prev Close36.75
ShortableYes LT Debt/Eq0.24 Earnings- Payout- Avg Volume68.76K Price37.94
Recom2.30 SMA204.74% SMA509.51% SMA20010.14% Volume121,601 Change3.24%
Jun-26-20Downgrade Goldman Neutral → Sell $34
Nov-20-19Initiated Evercore ISI Outperform
Nov-19-19Initiated Needham Buy $40
Nov-19-19Initiated Jefferies Buy $32
Nov-19-19Initiated Goldman Neutral $32
Sep-09-20 08:30AM  
Aug-06-20 08:30AM  
Jul-13-20 08:30AM  
Jun-15-20 08:30AM  
Jun-12-20 10:25PM  
May-28-20 04:30PM  
May-12-20 08:30AM  
Apr-09-20 04:30PM  
Mar-19-20 08:30AM  
Feb-25-20 04:35PM  
Jan-16-20 09:00AM  
Jan-06-20 08:30AM  
Dec-23-19 08:30AM  
Dec-02-19 08:30AM  
08:30AM  
Nov-26-19 08:30AM  
08:30AM  
Nov-25-19 08:30AM  
08:30AM  
Nov-13-19 04:05PM  
Oct-29-19 04:05PM  
Oct-25-19 05:10PM  
Oct-24-19 08:25PM  
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is based in Buffalo Grove, Illinois.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
RA CAPITAL MANAGEMENT, L.P.10% OwnerApr 01Buy24.86117,6002,923,6423,825,008Apr 03 04:30 PM
RA CAPITAL MANAGEMENT, L.P.10% OwnerMar 31Buy24.5530,600751,2643,707,408Mar 31 05:02 PM
RA CAPITAL MANAGEMENT, L.P.10% OwnerMar 27Buy24.6030,000738,0003,676,808Mar 31 05:02 PM